Key result
Effective antiviral agents for RSV infection remain necessary for infants and older children who do not benefit from recent vaccines and monoclonal antibodies.
Highlights the ongoing need for effective antiviral agents to treat RSV in infants and children who are ineligible for or do not benefit from new preventive interventions.
Infection with respiratory syncytial virus (RSV), the cause of annual winter epidemics of respiratory illness in all age groups, is best recognized for being the leading diagnosis in very young infants who are hospitalized. 1 The recent licensure of an RSV prefusion fusion protein (preF) vaccine to be administered during pregnancy and a long-acting preF monoclonal antibody for all newborns proximate to their first RSV season will, it is hoped, reduce hospitalizations. 2,3 Nevertheless, the need remains for an effective antiviral agent to treat infants and older children who are ineligible for or do not benefit from these new interventions. Aerosolized ribavirin, . . .
No takes yet. Share an insight, caveat, or question.
Edward E. Walsh (2024) conducted an editorial in Respiratory syncytial virus (RSV) infection. Antiviral agents was evaluated. Effective antiviral agents for RSV infection remain necessary for infants and older children who do not benefit from recent vaccines and monoclonal antibodies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: